2.

Summary of responses to first-line treatment in NSCLC patients harboring common and uncommon mutations

Variables	Responses to first-line EGFR-TKIs in NSCLC patients harboring common and uncommon mutations				Responses to different treatments in NSCLC patients harboring uncommon mutations
	EGFR mutation status		P		Treatment subgroup		P
	Common	Uncommon			Chemotherapy	TKIs
NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.
No. of patients	434	30			40	30
Response
CR	–	–			–	–
PR	225	7			11	7
SD	190	21			22	21
PD	19	2			7	2
ORR [n (%)]	225 (51.8)	7 (23.3)	0.003		11 (27.5)	7 (23.3)	0.693
DCR [n (%)]	415 (95.6)	28 (93.3)	0.897		33 (82.5)	28 (93.3)	0.328